{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-23-000019","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.793204+00:00","generated_at":"2026-06-19T01:25:51.045423+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeoGenomics Q4 revenue up 10% to $139M; net loss narrows to $23M; issues 2023 guidance with improved EBITDA","bullets":["Q4 revenue $139M (+10% YoY); full year revenue $510M (+5% YoY).","Q4 net loss $23M vs $42M loss in Q4 2021; full year net loss $144M vs $8M loss in 2021 (2021 included $109M Inivata gain).","Q4 adjusted EBITDA -$1.2M vs -$10M in Q4 2021; full year adjusted EBITDA -$48M vs -$4M in 2021.","2023 guidance: revenue $545-555M (7-9% growth), adjusted EBITDA $(27)-$(22)M (44-54% improvement).","Cash and marketable securities $438M at quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-23-000019","json":"https://secwatch.observer/filing/0001077183-23-000019.json","markdown":"https://secwatch.observer/filing/0001077183-23-000019.md","text":"https://secwatch.observer/filing/0001077183-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/0001077183-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/neo-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T01:25:51.045423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e66ba2d01f7539614c4e2510beb60e86be77638","claim":"NEOGENOMICS INC reported full year ended December 31, 2022 results: revenue $510 million, net income $144 million. Guidance initiated.","evidence_excerpt":"Consolidated revenue for 2022 was $510 million, an increase of 5% over 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/0001077183-23-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Revenue","value":"$510 million"},{"label":"Net income","value":"$144 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fbba58cefe4fab335f7d2c516a570552308fccf8","claim":"NEOGENOMICS INC reported the fourth quarter of 2022 results: revenue $139 million, net income $23 million. Guidance initiated.","evidence_excerpt":"Consolidated revenue for the fourth quarter of 2022 was $139 million, an increase of 10% over the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/0001077183-23-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"$139 million"},{"label":"Net income","value":"$23 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}